Pacific Price To Sales Ratio vs Payables Turnover Analysis

PACB Stock

USD 1.83 0.10 5.18%

Pacific Biosciences financial indicator trend analysis is much more than just breaking down Pacific Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pacific Biosciences is a good investment. Please check the relationship between Pacific Biosciences Price To Sales Ratio and its Payables Turnover accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Price To Sales Ratio vs Payables Turnover

Price To Sales Ratio vs Payables Turnover Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pacific Biosciences Price To Sales Ratio account and Payables Turnover. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Pacific Biosciences' Price To Sales Ratio and Payables Turnover is -0.19. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Payables Turnover in the same time period over historical financial statements of Pacific Biosciences of, assuming nothing else is changed. The correlation between historical values of Pacific Biosciences' Price To Sales Ratio and Payables Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Pacific Biosciences of are associated (or correlated) with its Payables Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Payables Turnover has no effect on the direction of Price To Sales Ratio i.e., Pacific Biosciences' Price To Sales Ratio and Payables Turnover go up and down completely randomly.

Correlation Coefficient

-0.19

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Pacific Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Pacific Biosciences sales, a figure that is much harder to manipulate than other Pacific Biosciences of multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most indicators from Pacific Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pacific Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

The current year's Selling General Administrative is expected to grow to about 177.3 M, whereas Tax Provision is forecasted to decline to (11.2 M).

	2021	2022	2023	2024 (projected)
Gross Profit	58.9M	49.0M	52.8M	28.1M
Total Revenue	130.5M	128.3M	200.5M	210.5M

Gross Profit Total Revenue

Pacific Biosciences fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Property Plant Equipment
Common Stock Shares Outstanding		0.87	0.87	0.6	0.91	0.89	0.22	0.82	0.59	0.82	-0.97	0.75	0.63	0.88	0.12	0.15	0.79	0.86	0.82	0.91	0.97	0.83	0.95	0.83	0.54	0.93
Total Assets	0.87		0.99	0.71	0.96	0.97	0.45	0.73	0.77	0.93	-0.82	0.71	0.75	0.99	0.09	-0.09	0.97	0.98	0.99	0.89	0.89	0.99	0.86	0.98	0.34	0.95
Short Long Term Debt Total	0.87	0.99		0.73	0.96	0.94	0.39	0.71	0.75	0.96	-0.84	0.74	0.69	1.0	0.13	-0.14	0.94	0.96	0.99	0.9	0.89	0.99	0.87	0.96	0.38	0.95
Other Current Liab	0.6	0.71	0.73		0.64	0.62	0.04	0.59	0.69	0.68	-0.59	0.52	0.59	0.71	0.34	0.15	0.69	0.68	0.75	0.58	0.59	0.75	0.5	0.7	0.44	0.65
Total Current Liabilities	0.91	0.96	0.96	0.64		0.96	0.34	0.67	0.7	0.93	-0.9	0.74	0.64	0.97	0.16	-0.04	0.9	0.94	0.92	0.93	0.95	0.93	0.9	0.92	0.41	0.94
Total Stockholder Equity	0.89	0.97	0.94	0.62	0.96		0.46	0.73	0.72	0.86	-0.84	0.68	0.76	0.95	0.05	0.0	0.95	0.98	0.91	0.89	0.91	0.92	0.87	0.96	0.29	0.93
Other Liab	0.22	0.45	0.39	0.04	0.34	0.46		0.39	0.64	0.24	-0.12	0.24	0.64	0.35	-0.2	-0.16	0.6	0.52	0.43	0.08	0.25	0.43	0.13	0.57	0.02	0.3
Property Plant And Equipment Net	0.82	0.73	0.71	0.59	0.67	0.73	0.39		0.66	0.59	-0.76	0.77	0.77	0.7	0.01	0.22	0.74	0.73	0.71	0.62	0.75	0.71	0.71	0.75	0.61	0.77
Current Deferred Revenue	0.59	0.77	0.75	0.69	0.7	0.72	0.64	0.66		0.62	-0.56	0.58	0.81	0.71	0.26	0.09	0.84	0.78	0.78	0.46	0.64	0.77	0.43	0.83	0.39	0.62
Net Debt	0.82	0.93	0.96	0.68	0.93	0.86	0.24	0.59	0.62		-0.83	0.74	0.47	0.97	0.16	-0.31	0.83	0.86	0.94	0.9	0.86	0.94	0.87	0.85	0.35	0.93
Retained Earnings	-0.97	-0.82	-0.84	-0.59	-0.9	-0.84	-0.12	-0.76	-0.56	-0.83		-0.8	-0.5	-0.86	-0.22	-0.1	-0.72	-0.79	-0.77	-0.89	-0.96	-0.78	-0.93	-0.75	-0.55	-0.91
Accounts Payable	0.75	0.71	0.74	0.52	0.74	0.68	0.24	0.77	0.58	0.74	-0.8		0.44	0.73	0.34	-0.07	0.63	0.64	0.7	0.64	0.78	0.71	0.71	0.66	0.65	0.79
Cash	0.63	0.75	0.69	0.59	0.64	0.76	0.64	0.77	0.81	0.47	-0.5	0.44		0.66	-0.01	0.35	0.87	0.82	0.72	0.5	0.6	0.72	0.5	0.85	0.28	0.61
Non Current Assets Total	0.88	0.99	1.0	0.71	0.97	0.95	0.35	0.7	0.71	0.97	-0.86	0.73	0.66		0.12	-0.15	0.92	0.95	0.98	0.92	0.9	0.98	0.9	0.94	0.36	0.96
Non Currrent Assets Other	0.12	0.09	0.13	0.34	0.16	0.05	-0.2	0.01	0.26	0.16	-0.22	0.34	-0.01	0.12		0.37	0.03	0.04	0.11	0.01	0.2	0.12	0.0	0.06	0.36	0.1
Other Assets	0.15	-0.09	-0.14	0.15	-0.04	0.0	-0.16	0.22	0.09	-0.31	-0.1	-0.07	0.35	-0.15	0.37		-0.02	0.01	-0.15	-0.08	0.08	-0.14	-0.06	-0.02	0.29	-0.12
Cash And Short Term Investments	0.79	0.97	0.94	0.69	0.9	0.95	0.6	0.74	0.84	0.83	-0.72	0.63	0.87	0.92	0.03	-0.02		0.99	0.95	0.77	0.81	0.95	0.74	1.0	0.3	0.87
Short Term Investments	0.86	0.98	0.96	0.68	0.94	0.98	0.52	0.73	0.78	0.86	-0.79	0.64	0.82	0.95	0.04	0.01	0.99		0.95	0.85	0.87	0.95	0.82	0.99	0.29	0.91
Non Current Liabilities Total	0.82	0.99	0.99	0.75	0.92	0.91	0.43	0.71	0.78	0.94	-0.77	0.7	0.72	0.98	0.11	-0.15	0.95	0.95		0.85	0.84	1.0	0.81	0.96	0.36	0.92
Other Current Assets	0.91	0.89	0.9	0.58	0.93	0.89	0.08	0.62	0.46	0.9	-0.89	0.64	0.5	0.92	0.01	-0.08	0.77	0.85	0.85		0.9	0.86	0.97	0.81	0.3	0.92
Other Stockholder Equity	0.97	0.89	0.89	0.59	0.95	0.91	0.25	0.75	0.64	0.86	-0.96	0.78	0.6	0.9	0.2	0.08	0.81	0.87	0.84	0.9		0.85	0.93	0.84	0.5	0.93
Total Liab	0.83	0.99	0.99	0.75	0.93	0.92	0.43	0.71	0.77	0.94	-0.78	0.71	0.72	0.98	0.12	-0.14	0.95	0.95	1.0	0.86	0.85		0.82	0.96	0.37	0.93
Property Plant And Equipment Gross	0.95	0.86	0.87	0.5	0.9	0.87	0.13	0.71	0.43	0.87	-0.93	0.71	0.5	0.9	0.0	-0.06	0.74	0.82	0.81	0.97	0.93	0.82		0.78	0.39	0.94
Total Current Assets	0.83	0.98	0.96	0.7	0.92	0.96	0.57	0.75	0.83	0.85	-0.75	0.66	0.85	0.94	0.06	-0.02	1.0	0.99	0.96	0.81	0.84	0.96	0.78		0.32	0.89
Short Term Debt	0.54	0.34	0.38	0.44	0.41	0.29	0.02	0.61	0.39	0.35	-0.55	0.65	0.28	0.36	0.36	0.29	0.3	0.29	0.36	0.3	0.5	0.37	0.39	0.32		0.39
Property Plant Equipment	0.93	0.95	0.95	0.65	0.94	0.93	0.3	0.77	0.62	0.93	-0.91	0.79	0.61	0.96	0.1	-0.12	0.87	0.91	0.92	0.92	0.93	0.93	0.94	0.89	0.39

Click cells to compare fundamentals

Pacific Biosciences Account Relationship Matchups

Pacific Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	152.5M	175.0M	204.1M	224.6M	253.6M	266.3M
Total Assets	148.0M	414.0M	2.0B	1.8B	1.7B	1.8B
Short Long Term Debt Total	61.7M	42.0M	953.7M	957.4M	933.9M	980.6M
Other Current Liab	(13.9M)	17.5M	40.4M	201.2M	53.5M	56.2M
Total Current Liabilities	21.8M	36.5M	83.3M	76.9M	95.0M	99.8M
Total Stockholder Equity	54.9M	335.5M	791.0M	562.9M	701.3M	736.4M
Other Liab	2.0M	10.3M	215.0M	2.6M	3.0M	2.8M
Property Plant And Equipment Net	62.9M	54.9M	79.1M	81.3M	69.0M	35.5M
Current Deferred Revenue	7.6M	10.3M	36.0M	32.3M	16.3M	13.1M
Net Debt	12.6M	(276.8M)	493.0M	632.3M	754.0M	791.7M
Retained Earnings	(1.1B)	(1.0B)	(1.2B)	(1.5B)	(1.8B)	(1.7B)
Accounts Payable	8.4M	3.6M	11.0M	12.0M	15.1M	7.6M
Cash	49.1M	318.8M	460.7M	325.1M	179.9M	137.4M
Non Current Assets Total	66.9M	59.2M	901.2M	912.1M	1.0B	1.1B
Non Currrent Assets Other	42K	879K	1.2M	10.5M	3.7M	3.7M
Other Assets	4.0M	33.5M	1.2M	13.5M	1.0	0.95
Cash And Short Term Investments	49.1M	318.8M	1.0B	772.3M	631.4M	663.0M
Short Term Investments	19.5M	237.2M	583.7M	447.2M	451.5M	474.1M
Liabilities And Stockholders Equity	148.0M	414.0M	2.0B	1.8B	1.7B	1.8B
Non Current Liabilities Total	71.2M	42.0M	1.1B	1.1B	949.7M	997.2M
Other Current Assets	3.4M	5.7M	7.9M	10.6M	17.3M	18.2M
Other Stockholder Equity	1.1B	1.4B	2.0B	2.1B	2.5B	2.7B
Total Liab	93.1M	78.5M	1.2B	1.2B	1.0B	1.1B
Property Plant And Equipment Gross	62.9M	54.9M	79.1M	81.3M	143.8M	151.0M
Total Current Assets	81.0M	354.8M	1.1B	855.0M	742.0M	779.1M
Short Term Debt	19.7M	8.7M	9.3M	19.6M	10.1M	8.2M
Property Plant Equipment	30.1M	24.9M	79.1M	81.3M	93.5M	98.2M
Long Term Debt	14.7M	15.9M	896.1M	896.7M	892.2M	936.9M
Net Receivables	15.3M	16.8M	24.2M	18.8M	36.6M	38.4M
Common Stock Total Equity	150K	153K	192K	221K	198.9K	189.0K
Inventory	13.3M	14.2M	24.6M	50.4M	56.7M	59.5M
Common Stock	153K	192K	221K	227K	268K	254.6K
Net Tangible Assets	54.9M	335.5M	(30.0M)	(257.3M)	(231.6M)	(220.0M)
Retained Earnings Total Equity	(982.1M)	(1.1B)	(1.0B)	(1.2B)	(1.1B)	(1.2B)
Capital Surpluse	1.1B	1.1B	1.4B	2.0B	2.3B	1.2B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

When determining whether Pacific Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pacific Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pacific Biosciences Of Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pacific Biosciences Of Stock:

How To Invest In Pacific

Details

Is Pacific Stock a good investment?

Details

What is Pacific Biosciences' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacific Biosciences of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacific Biosciences. If investors know Pacific will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacific Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.46)

Revenue Per Share

0.64

Quarterly Revenue Growth

(0.28)

Return On Assets

(0.11)

Return On Equity

(0.65)

The market value of Pacific Biosciences is measured differently than its book value, which is the value of Pacific that is recorded on the company's balance sheet. Investors also form their own opinion of Pacific Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pacific Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacific Biosciences' market value can be influenced by many factors that don't directly affect Pacific Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pacific Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacific Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacific Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pacific Price To Sales Ratio vs Payables Turnover Analysis

Price To Sales Ratio vs Payables Turnover

Price To Sales Ratio vs Payables Turnover Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Payables Turnover

Pacific Biosciences fundamental ratios Correlations

Pacific Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pacific Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Short Long Term Debt Total
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Short Long Term Debt Total	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Total Assets

Retained Earnings	- 0.97	Common Stock Shares Outstanding
Other Stockholder Equity	- 0.96	Retained Earnings
Property Plant And Equipment Gross	- 0.93	Retained Earnings
Property Plant Equipment	- 0.91	Retained Earnings
Retained Earnings	- 0.9	Total Current Liabilities
Other Current Assets	- 0.89	Retained Earnings